Mitchell Mutz, PhD, is a Senior Principal at Samsara BioCapital. He is a successful biotech entrepreneur, venture investor, and inventor with over 20 years experience in starting and investing in biotechnology companies. Mitchell was previously Entrepreneur Partner at Vivo Capital where he led investments in EpiBiologics and Bonum Therapeutics. Prior to that, Mitchell was a Senior Investment Director at the Roche Venture Fund. Deals led included Pandion Therapeutics (acquired by Merck), Good Therapeutics (acquired by Roche),Enliven Therapeutics (NASDAQ:ELVN), and Nimble Therapeutics (acquired by Abbvie).
Previously, Mitchell was a co-founder, president, and chief scientific officer of Amplyx Pharmaceuticals, Inc., a biotherapeutics company, acquired by Pfizer. Mitchell was also on the founding team and the Principal Scientist of Labcyte, a tools company he helped grow from inception and was later acquired by Beckman-Coulter, Inc. He is also an inventor on 38 issued patents.
Mitchell earned a Ph.D. in Chemistry from the University of Rochester, a Diploma in Orchestral Studies from the University of London, UK, and a B.A. in Chemistry with high honors from Oberlin College.